0000950170-25-002425.txt : 20250106 0000950170-25-002425.hdr.sgml : 20250106 20250106190403 ACCESSION NUMBER: 0000950170-25-002425 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250102 FILED AS OF DATE: 20250106 DATE AS OF CHANGE: 20250106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Campbell Bradley L CENTRAL INDEX KEY: 0001400971 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 25512928 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS, INC. STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 47 HULFISH STREET CITY: PRINCETON STATE: NJ ZIP: 08542 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 47 HULFISH STREET CITY: PRINCETON STATE: NJ ZIP: 08542 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 4 1 ownership.xml 4 X0508 4 2025-01-02 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001400971 Campbell Bradley L 47 HULFISH STREET PRINCETON NJ 08542 true true false false President and CEO false Common Stock 2025-01-02 4 F false 20647 9.31 D 866007 D Common Stock 2025-01-03 4 A false 266528 0 A 1132535 D Common Stock 2025-01-03 4 F false 41474 9.41 D 1091061 D Common Stock 2025-01-04 4 F false 7368 9.41 D 1083693 D Stock Options (right to buy) 9.41 2025-01-03 4 A false 482908 0.0 A 2035-01-03 Common Stock 482908 482908 D Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in four equal annual installments beginning on January 3, 2026 and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. /s/ Christian Formica, Attorney-in-Fact 2025-01-06